Horizon Therapeutics Reports P-IV Clinical Trial Results of Tepezza (teprotumumab-trbw) for Chronic/Low Clinical Activity Score Thyroid Eye Disease
Shots:
- The company highlighted the results from the P-IV clinical trial evaluating the efficacy and safety of Tepezza vs PBO in adults aged 2-20yrs. with chronic TED and low CAS
- The trial met its 1EPs & showed that patients treated with Tepezza achieved a significant reduction in proptosis from baseline (2.41mm vs 0.92mm) in the pre-specified primary analysis method (intent-to-treat) while (2.44mm vs 0.69mm) in the pre-specified per-protocol analysis @24wk.
- In intent-to-treat & per protocol, improvement in proptosis responder rate (62% vs 25%) & (63% vs 7%), no new safety signals were reported. The company also plans to present the results at a future medical congress and publish them in a peer-reviewed medical journal
Ref: Horizon Therapeutics | Image: Horizon Therapeutics
Related Post:- Horizon Therapeutics to Acquire Viela Bio for ~ $3.05B
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
